Nephrology
End-Stage Renal Disease
2
Pipeline Programs↗
9
Active Trials↗
28
Companies Involved↗
End-Stage Renal Disease is an early-stage landscape with 2 programs across 28 companies. The most active players are Xeno Holdings (US), LLC dba ChoironeX, AstraZeneca, Celltex Therapeutics Corporation.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 12
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
3programs
Small molecule133%
Monoclonal antibody133%
Cell therapy133%
Modality classified for 75% of 4 pipeline programs.
Analysis
Trial Status
80
clinical trials
Completed58 · 73%
Unknown status6 · 8%
Withdrawn5 · 6%
Recruiting5 · 6%
Not yet recruiting3 · 4%
Terminated2 · 3%
Other1 · 1%
Clinical Trials
Trial Activity
80 trials
Glucose Disorders Induced by Tacrolimus on Pre Transplantation Endstage Renal Disease Patients
Recruiting·—·Phase 4·NCT03640026·30 enrolled
A Phase I, Open Label Study of Allogeneic Adipose Derived Mesenchymal Stem Cells in Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
Recruiting·—·Phase 1·NCT04392206·15 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)